trending Market Intelligence /marketintelligence/en/news-insights/trending/CfPPQDh_H9ymAxNDRcyuKA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

J&J, Bayer to pay $775M to settle US lawsuits over blood thinner Xarelto

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


J&J, Bayer to pay $775M to settle US lawsuits over blood thinner Xarelto

Johnson & Johnson and Bayer AG agreed to pay about $775 million to settle almost all of the approximately 25,000 suits in the U.S. related to their blockbuster blood-thinning drug Xarelto.

The settlement amount will be equally shared by the two companies.

Plaintiffs in the lawsuit had alleged that the drug caused uncontrollable and irreversible bleeding that led to injuries and even deaths. The companies were accused of not making patients and doctors aware of any bleeding risks related to the drug, Reuters reported.

Bayer said in a March 25 press release that the claims are without merit and there is no admission of liability under the agreement. The company said the settlement will allow it to avoid distraction and the significant cost of continued litigation.

Bayer added that the safety profile of the medicine remains positive and unchanged and that its share of the settlement will be partially covered by product liability insurance.

J&J said in a statement that the settlement was the right move and that the company continues to stand by the safety profile of the drug, Reuters reported.

Xarelto, jointly developed by New Brunswick, N.J.-based Johnson & Johnson and Germany-based Bayer, generated sales of about €3.63 billion for Bayer and about $2.48 billion for J&J in 2018.

J&J sells the medicine in the U.S., while Bayer sells it worldwide.